A comprehensive view of OPKO Health Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Opko Health swings to Q1 net loss of US$55.4M from net income of US$31.1M a year ago, with consolidated revenue down at US$329.2M from US$545.2M a year ago; diagnostics revenue down at US$286.6M due to fewer COVID-19 tests, pharmaceuticals up at US$36.6M

Biopharmaceutical, diagnostics firm OPKO Health completes acquisition of ModeX Therapeutics for US$300M; ModeX Therapeutics develops multi-specific immune therapies for cancer and infectious diseases

Pfizer and OPKO Health announce European Commission marketing authorization for NGENLA, a human growth hormone product, for children and adolescents aged three and older with growth hormone insufficiency

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count